BioAge Labs (NASDAQ:BIOA) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded BioAge Labs to “strong sell”, despite the broader analyst consensus remaining “Moderate Buy,” with six Buy ratings and one Sell rating.
• BioAge shares opened at $6.34, near their 12-month low of $5.04 and well below the average analyst price target of $36.57. The company has a market capitalization of approximately $291 million and remains unprofitable.
• BioAge reported a quarterly loss of $0.58 per share, better than the expected $0.65 loss, on $2.45 million in revenue. Several institutional investors, including BlackRock and Jupiter Topco, recently initiated or increased positions.

BioAge Labs (NASDAQ:BIOA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other analysts have also recently weighed in on the company. Needham & Company LLC reduced their price target on BioAge Labs from $50.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a report on Friday, July 31st. Weiss Ratings downgraded BioAge Labs from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday. BTIG Research restated a "buy" rating and issued a $40.00 target price on shares of BioAge Labs in a report on Tuesday, September 8th. Finally, Roth Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of BioAge Labs in a research report on Wednesday, September 9th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioAge Labs presently has an average rating of "Moderate Buy" and an average target price of $36.57.

BioAge Labs Stock Up 2.1%

BIOA stock opened at $6.34 on Friday. The firm has a 50 day moving average of $8.96 and a two-hundred day moving average of $15.56. BioAge Labs has a 12 month low of $5.04 and a 12 month high of $25.95. The company has a market capitalization of $291.01 million, a price-to-earnings ratio of -2.66 and a beta of 1.08.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. On average, research analysts expect that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in BioAge Labs during the second quarter valued at approximately $69,831,000. Jupiter Topco LLC acquired a new position in shares of BioAge Labs in the 2nd quarter worth approximately $52,597,000. Janus Henderson Group PLC lifted its position in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock worth $36,597,000 after buying an additional 1,685,063 shares during the period. Octagon Capital Advisors LP lifted its position in shares of BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company's stock worth $30,573,000 after buying an additional 150,000 shares during the period. Finally, Walleye Capital LLC acquired a new stake in BioAge Labs in the 2nd quarter valued at $8,686,000.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge's pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.